Screener
Anika Therapeutics ANIK Business Segments — Total Costs & Expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Anika Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CostsAndExpenses.
The source filing: Anika Therapeutics’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001171843-26-005012
| Line item | For the Three Months Ended June 30, 2026 | For the Three Months Ended June 30, 2025 | For the Six Months Ended June 30, 2026 | For the Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Operating expenses: | ||||
| Research & development | 7,341 | 6,313 | 14,054 | 12,372 |
| Selling, general & administrative | 10,949 | 12,230 | 28,721 | 25,136 |
| Total operating expenses | 18,290 | 18,543 | 42,775 | 37,508 |
| Income (loss) from operations | 2,954 | (4,180) | (2,534) | (8,464) |
| Interest and other income, net | 426 | 214 | 1,093 | 629 |
| Income (loss) before income taxes | 3,380 | (3,966) | (1,441) | (7,835) |
| Provision for income taxes | 71 | 681 | 306 | 770 |
ITEM 1. FINANCIAL STATEMENTS[ Item 1. Condensed Consolidated Financial Statements (unaudited): ](#)
FAQ
- What is Anika Therapeutics's business segments — total costs & expenses?
- Anika Therapeutics (ANIK) reported business segments — total costs & expenses of $18.29M in Q2 2026.
- What does business segments — total costs & expenses mean?
- This represents the aggregate of all operating costs, including production, research, and administrative expenses incurred by the business segment. It is used to assess the total operational burden required to sustain the company's orthopedic operations.
Ask your AI about Anika Therapeutics's business segments — total costs & expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude